CSIMarket Company Name, Ticker, Customers, else..
 

Syndax Pharmaceuticals Inc   (NASDAQ: SNDX)

Syndax Pharmaceuticals Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

SNDX Sales vs. its Competitors Q2 2026


Comparing the current results to its competitors, Syndax Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 91.76 % year on year.
The sales growth was above Syndax Pharmaceuticals Inc 's competitors' average revenue growth of 33.11 %, achieved in the same quarter.

• List of SNDX Competitors





Revenue Growth Comparisons




Net Income Comparison

Syndax Pharmaceuticals Inc recorded a net loss, as well as most of its competitors.

<<  SNDX Stock Performance Comparisons


Syndax Pharmaceuticals Inc 's Comment on Competition and Industry Peers


The competitive landscape includes developments involving competitors and the industry, with specific reference to the market adoption of REVUFORJ® (revumenib) and NIKTIMVO™ (axatilimab-csfr) by physicians and patients. Geopolitical actions and global economic conditions may also affect operations and collaborations.



  

Overall company Market Share Q2 2026
Due to outstanding performance in Overall company, revenue grew by 91.76 % Syndax Pharmaceuticals Inc improved its market share, to approximately 20.87 %.




<<  More on SNDX Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Syndax Pharmaceuticals Inc




Zymeworks Inc
Share Performance



+11.99%
This Quarter
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,051.842 mill. $ 37.127 mill. $ -149.992 mill.


Protagonist Therapeutics inc
Share Performance



+150.07%
One Year
Protagonist Therapeutics inc
Profile

Protagonist Therapeutics Inc's business model focuses on the development and commercialization of novel peptide-based therapeutics.

More about Protagonist Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 10,287.693 mill. $ 74.063 mill. $ -116.272 mill.


Pliant Therapeutics Inc
Share Performance



-2.99%
This Quarter
Pliant Therapeutics Inc
Profile

Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.

More about Pliant Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 70.278 mill. $ - mill. $ -92.289 mill.


Phio Pharmaceuticals Corp
Share Performance



-9.65%
This Quarter
Phio Pharmaceuticals Corp
Profile

Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.

More about Phio Pharmaceuticals Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11.966 mill. $ - mill. $ -12.904 mill.


Oncotelic Therapeutics Inc
Share Performance



0.00%
Over The Past 5 Days
Oncotelic Therapeutics Inc
Profile

Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.

More about Oncotelic Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 14.037 mill. $ 0.250 mill. $ 247.280 mill.

49 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Syndax Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Syndax Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.